血浆容量状态预测经导管边缘到边缘二尖瓣修复患者的临床结果。

IF 3.7 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN-Mitral Investigators
{"title":"血浆容量状态预测经导管边缘到边缘二尖瓣修复患者的临床结果。","authors":"Ai Kagase,&nbsp;Masanori Yamamoto,&nbsp;Takahiro Tokuda,&nbsp;Ryotaku Kawahata,&nbsp;Hiroto Nishio,&nbsp;Tetsuro Shimura,&nbsp;Ryo Yamaguchi,&nbsp;Mitsuru Sago,&nbsp;Yuki Izumi,&nbsp;Mike Saji,&nbsp;Masahiko Asami,&nbsp;Yusuke Enta,&nbsp;Masaki Nakashima,&nbsp;Shinichi Shirai,&nbsp;Masaki Izumo,&nbsp;Shingo Mizuno,&nbsp;Yusuke Watanabe,&nbsp;Makoto Amaki,&nbsp;Kazuhisa Kodama,&nbsp;Junichi Yamaguchi,&nbsp;Toru Naganuma,&nbsp;Hiroki Bouta,&nbsp;Yohei Ohno,&nbsp;Masahiro Yamawaki,&nbsp;Hiroshi Ueno,&nbsp;Kazuki Mizutani,&nbsp;Daisuke Hachinohe,&nbsp;Toshiaki Otsuka,&nbsp;Shunsuke Kubo,&nbsp;Kentaro Hayashida,&nbsp;OCEAN-Mitral Investigators","doi":"10.1002/ehf2.15295","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.</p>\n </section>\n \n <section>\n \n <h3> Methods and results</h3>\n \n <p>Data from 3763 patients who underwent M-TEER were analysed from a Japanese multicentre registry. Patients were classified into functional MR (FMR) and degenerative MR (DMR) according to MR aetiology, and the median PVS values for each were calculated (FMR 12.7, DMR 14.4). The median value was used as the cut-off, stratifying the cohort into a high PVS group (<i>n</i> = 1882) and a low PVS group (<i>n</i> = 1881). All-cause mortality, cardiovascular death, and heart failure (HF) hospitalization between these two groups were compared up to 3 years in the overall, FMR, and DMR populations. The cumulative incidence rates of all-cause mortality, cardiovascular death, and HF hospitalization were higher in the high PVS group than in the low PVS group (47.0% vs. 22.2%, <i>P</i> &lt; 0.001, 31.6% vs. 13.6%, <i>P</i> &lt; 0.001, and 35.9% vs. 24.7%, <i>P</i> &lt; 0.001, respectively). Similar trends in terms of all-cause mortality, cardiovascular death, and HF hospitalization were observed in the FMR and DMR cohorts (all <i>P</i> &lt; 0.05). In the multivariate Cox regression analysis, the high PVS compared with the low PVS group was independently associated with the increased risk of all-cause death (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01–1.03; <i>P</i> &lt; 0.001), cardiovascular death (HR, 1.02; 95% CI, 1.01–1.03, <i>P</i> &lt; 0.001) and HF hospitalization (HR, 1.02; 95% CI, 1.01–1.02, <i>P</i> &lt; 0.001). An independent association between a high PVS and all-cause death, cardiovascular death, and HF hospitalization was also found in FMR and DMR sub-groups (all <i>P</i> &lt; 0.05) while reducing MR severity to moderate or less after M-TEER was associated with improved outcomes in both the high and low PVS groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Preoperative PVS is a strong independent prognostic marker in patients undergoing M-TEER, correlating with increased risk of mortality and HF hospitalization. PVS may provide valuable clinical insights for patient stratification and management strategies in M-TEER patients.</p>\n </section>\n </div>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 4","pages":"2855-2865"},"PeriodicalIF":3.7000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15295","citationCount":"0","resultStr":"{\"title\":\"Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair\",\"authors\":\"Ai Kagase,&nbsp;Masanori Yamamoto,&nbsp;Takahiro Tokuda,&nbsp;Ryotaku Kawahata,&nbsp;Hiroto Nishio,&nbsp;Tetsuro Shimura,&nbsp;Ryo Yamaguchi,&nbsp;Mitsuru Sago,&nbsp;Yuki Izumi,&nbsp;Mike Saji,&nbsp;Masahiko Asami,&nbsp;Yusuke Enta,&nbsp;Masaki Nakashima,&nbsp;Shinichi Shirai,&nbsp;Masaki Izumo,&nbsp;Shingo Mizuno,&nbsp;Yusuke Watanabe,&nbsp;Makoto Amaki,&nbsp;Kazuhisa Kodama,&nbsp;Junichi Yamaguchi,&nbsp;Toru Naganuma,&nbsp;Hiroki Bouta,&nbsp;Yohei Ohno,&nbsp;Masahiro Yamawaki,&nbsp;Hiroshi Ueno,&nbsp;Kazuki Mizutani,&nbsp;Daisuke Hachinohe,&nbsp;Toshiaki Otsuka,&nbsp;Shunsuke Kubo,&nbsp;Kentaro Hayashida,&nbsp;OCEAN-Mitral Investigators\",\"doi\":\"10.1002/ehf2.15295\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods and results</h3>\\n \\n <p>Data from 3763 patients who underwent M-TEER were analysed from a Japanese multicentre registry. Patients were classified into functional MR (FMR) and degenerative MR (DMR) according to MR aetiology, and the median PVS values for each were calculated (FMR 12.7, DMR 14.4). The median value was used as the cut-off, stratifying the cohort into a high PVS group (<i>n</i> = 1882) and a low PVS group (<i>n</i> = 1881). All-cause mortality, cardiovascular death, and heart failure (HF) hospitalization between these two groups were compared up to 3 years in the overall, FMR, and DMR populations. The cumulative incidence rates of all-cause mortality, cardiovascular death, and HF hospitalization were higher in the high PVS group than in the low PVS group (47.0% vs. 22.2%, <i>P</i> &lt; 0.001, 31.6% vs. 13.6%, <i>P</i> &lt; 0.001, and 35.9% vs. 24.7%, <i>P</i> &lt; 0.001, respectively). Similar trends in terms of all-cause mortality, cardiovascular death, and HF hospitalization were observed in the FMR and DMR cohorts (all <i>P</i> &lt; 0.05). In the multivariate Cox regression analysis, the high PVS compared with the low PVS group was independently associated with the increased risk of all-cause death (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01–1.03; <i>P</i> &lt; 0.001), cardiovascular death (HR, 1.02; 95% CI, 1.01–1.03, <i>P</i> &lt; 0.001) and HF hospitalization (HR, 1.02; 95% CI, 1.01–1.02, <i>P</i> &lt; 0.001). An independent association between a high PVS and all-cause death, cardiovascular death, and HF hospitalization was also found in FMR and DMR sub-groups (all <i>P</i> &lt; 0.05) while reducing MR severity to moderate or less after M-TEER was associated with improved outcomes in both the high and low PVS groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Preoperative PVS is a strong independent prognostic marker in patients undergoing M-TEER, correlating with increased risk of mortality and HF hospitalization. PVS may provide valuable clinical insights for patient stratification and management strategies in M-TEER patients.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11864,\"journal\":{\"name\":\"ESC Heart Failure\",\"volume\":\"12 4\",\"pages\":\"2855-2865\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ehf2.15295\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESC Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15295\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15295","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:血浆容量状态(PVS)被认为是全身充血的标志,但其在二尖瓣返流(MR)患者中进行经导管边缘到边缘二尖瓣修复(M-TEER)的临床应用尚未得到很好的证实。本研究旨在评估PVS在这些患者中的预后意义。方法和结果:来自日本多中心注册中心的3763例接受M-TEER的患者的数据进行了分析。根据MR病因将患者分为功能性MR (FMR)和退行性MR (DMR),并计算每组患者的中位pv值(FMR 12.7, DMR 14.4)。采用中位数作为临界值,将队列分为高pv组(n = 1882)和低pv组(n = 1881)。这两组的全因死亡率、心血管死亡率和心力衰竭住院率在总体、FMR和DMR人群中进行了长达3年的比较。高PVS组的全因死亡率、心血管死亡和HF住院的累积发生率高于低PVS组(47.0% vs 22.2%), P结论:术前PVS是M-TEER患者的一个强大的独立预后指标,与死亡和HF住院风险增加相关。PVS可能为M-TEER患者的患者分层和管理策略提供有价值的临床见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair

Aims

Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge-to-edge mitral valve repair (M-TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.

Methods and results

Data from 3763 patients who underwent M-TEER were analysed from a Japanese multicentre registry. Patients were classified into functional MR (FMR) and degenerative MR (DMR) according to MR aetiology, and the median PVS values for each were calculated (FMR 12.7, DMR 14.4). The median value was used as the cut-off, stratifying the cohort into a high PVS group (n = 1882) and a low PVS group (n = 1881). All-cause mortality, cardiovascular death, and heart failure (HF) hospitalization between these two groups were compared up to 3 years in the overall, FMR, and DMR populations. The cumulative incidence rates of all-cause mortality, cardiovascular death, and HF hospitalization were higher in the high PVS group than in the low PVS group (47.0% vs. 22.2%, P < 0.001, 31.6% vs. 13.6%, P < 0.001, and 35.9% vs. 24.7%, P < 0.001, respectively). Similar trends in terms of all-cause mortality, cardiovascular death, and HF hospitalization were observed in the FMR and DMR cohorts (all P < 0.05). In the multivariate Cox regression analysis, the high PVS compared with the low PVS group was independently associated with the increased risk of all-cause death (hazard ratio [HR], 1.02; 95% confidence interval [CI], 1.01–1.03; P < 0.001), cardiovascular death (HR, 1.02; 95% CI, 1.01–1.03, P < 0.001) and HF hospitalization (HR, 1.02; 95% CI, 1.01–1.02, P < 0.001). An independent association between a high PVS and all-cause death, cardiovascular death, and HF hospitalization was also found in FMR and DMR sub-groups (all P < 0.05) while reducing MR severity to moderate or less after M-TEER was associated with improved outcomes in both the high and low PVS groups.

Conclusions

Preoperative PVS is a strong independent prognostic marker in patients undergoing M-TEER, correlating with increased risk of mortality and HF hospitalization. PVS may provide valuable clinical insights for patient stratification and management strategies in M-TEER patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信